Protagen AG and MicroDiscovery GmbH cooperate in biomarker development

18 Oct 2010 - Dortmund based Protagen AG and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases.

"Our proprietary technology platform UNIarray® and MicroDiscovery's certified software solutions for the analysis of complex marker panels complement each other perfectly," states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics of Protagen AG and adds: "The cooperation strengthens our position in biomarker development and supports the efficient development of marketable products."

Dr. Arif Malik, CEO of MicroDiscovery GmbH, confirms: "Our experience in analyzing clinical studies for multiplex assays and array data perfectly fits with Protagen's established screening platform. This illustrates the value of MicroDiscovery's bioinformatics methods and software solutions for the development of new diagnostics."

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.